Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
Authors:
Open Access
- 8 November 2020
- journal article
- research article
- Published by Wiley in ACR Open Rheumatology
- Vol. 2 (11) , 672-680
Abstract
Objective: This post hoc analysis evaluated the safety and efficacy of open‐label sarilumab in patients with rheumatoid arthritis (RA) who completed the phase III double‐blind ASCERTAIN study (NCT01768572) and switched from intravenous (IV) tocilizumab to subcutaneous (SC) sarilumab, or who continued SC sarilumab in the open‐label extension (OLE) study EXTEND (NCT01146652).Methods: Patients who completed ASCERTAIN were eligible to enroll in EXTEND to receive sarilumab 200 mg SC every 2 weeks (Q2W). Safety and efficacy were reported through 96 weeks in the OLE in patients who switched from tocilizumab IV to sarilumab 200 mg SC Q2W, who switched from sarilumab 150 mg SC Q2W to sarilumab 200 mg SC Q2W, or who continued sarilumab 200 mg SC Q2W.Results: Of 175 patients who completed ASCERTAIN, 168 (96%) enrolled in EXTEND, and 38 of these patients (23%) discontinued the OLE. Cumulative sarilumab exposure during follow‐up was 273.7 patient‐years. No new safety signals were identified, infections occurred at a rate of 59.9/100 patient‐years, and there were no cases of grade 4 neutropenia. Efficacy—as assessed by Disease Activity Score (28 joints) based on C‐reactive protein, Clinical Disease Activity Index, and Health Assessment Questionnaire‐Disability Index scores—was sustained over 96 weeks of follow‐up when switching to, or continuing, sarilumab 200 mg SC Q2W.Conclusion: Switching from IV to SC interleukin‐6 receptor inhibitor therapy produced no new safety concerns, and clinical efficacy was sustained over 96 weeks of follow‐up. These findings alleviate potential concerns over switching route of administration with interleukin‐6 receptor inhibitor therapy for RA.Keywords
This publication has 22 references indexed in Scilit:
- Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 PatientsThe Journal of Rheumatology, 2015
- The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injectionPatient Preference and Adherence, 2015
- Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid ArthritisArthritis Care & Research, 2015
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyArthritis & Rheumatology, 2015
- IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and futureArchives of Pharmacal Research, 2015
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyAnnals of Oncology, 2014
- Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic ReviewThe Patient - Patient-Centered Outcomes Research, 2014
- Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE studyAnnals of the Rheumatic Diseases, 2012
- Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis & Rheumatism, 2006
- Patient preferences in choosing anti-TNF therapies-R1Rheumatology, 2006